Elif Şahin
A5086059674- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Gastric Cancer Management and Outcomes
- Cancer-related Molecular Pathways
- HER2/EGFR in Cancer Research
- Inflammatory Biomarkers in Disease Prognosis
- Chronic Lymphocytic Leukemia Research
- Cancer, Lipids, and Metabolism
- Hepatitis C virus research
- Cutaneous Melanoma Detection and Management
- Prostate Cancer Treatment and Research
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Esophageal Cancer Research and Treatment
- Inflammatory Myopathies and Dermatomyositis
- Colorectal Cancer Treatments and Studies
- Monoclonal and Polyclonal Antibodies Research
- Gastrointestinal Tumor Research and Treatment
- Cancer Risks and Factors
- Frailty in Older Adults
- Liver Diseases and Immunity
- Cutaneous lymphoproliferative disorders research
- Misinformation and Its Impacts
- Body Composition Measurement Techniques
Kocaeli Üniversitesi
2020-2025
Hacettepe University
2025
Sakarya University
2022
Sanko University
2016
Namık Kemal University
2016
There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which oncologists prefer patients with disease progression under CDKi. In addition, we show the effectiveness of systemic treatments CDKi and whether there a survival difference between hormonal (monotherapy vs. mTOR-based).A total 609 from 53 centers were included study....
Central nervous system (CNS) metastases can be seen at a rate of 30% in advanced stages for patients with non-small cell lung cancer (NSCLC). Growing evidence indicates the predictive roles driver gene mutations development brain (BM) recent years, meaning that oncogene-driven NSCLC have high incidence BM diagnosis. Today, 3rd generation targeted drugs intracranial efficacy, which cross blood-brain barrier, made positive contribution to survival these an increased propensity BM. It is...
Management of melanoma has changed significantly with the discovery targeted therapies and immune checkpoint inhibitors (ICI). Our aim in study is to determine which treatment alternatives, specifically dabrafenib plus trametinib ICIs, are effective adjuvant therapy as first-line metastatic therapy. This retrospective, multicenter included 120 patients diagnosed stage IIIB-IIID receiving both between 2007 2023. Data on clinicopathologic characteristics, regimens outcomes were collected....
ABSTRACT Background Fear of cancer recurrence (FCR) is a pervasive concern among lymphoma survivors and their family caregivers, influencing psychological physical health. Given the substantial burden FCR, identifying its predictors crucial for targeted interventions that could enhance palliative care. We aimed to evaluate prevalence FCR in as well associated factors Methods A total 118 patients with lymphoma, along were recruited from Hacettepe University Cancer Institute between March 2024...
Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase as the first-line standard-of-care for patients hormone receptor-positive, HER2-negative metastatic breast cancer.
This study is aimed to investigate the prognostic significance of inflammation indices, including neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte (MLR), platelet-to-lymphocyte (PLR), systemic immune-inflammation index (SII), and pan-immune-inflammation value (PIV) in metastatic castration-resistant prostate cancer (mCRPC) patients who had received lutetium labeled prostate-specific membrane antigen ( 177 Lu–PSMA-617) therapy. Sixty-one mCRPC Lu–PSMA-617 treatment followed up...
We investigated the serum levels of MMPs and TIMPs in breast cancer (BC) patients to predict response rate to/after treatment with or without neoadjuvant chemotherapy. BC is most common women are responsible for breakdown ECM proteins during organogenesis restricted destruction by MMPs. However, predictive role has not identified.This study consisted 96 (34 62 surgically treated) 35 healthy individuals. ELISA was used determine level MMP-2, MMP-9, TIMP-1, TIMP-2 from samples patients.The...
Real-world (RW) data provide valuable information about the effectiveness and safety of treatment modalities in general population that is not limited by selection criteria clinical studies. The aim this study was to evaluate palbociclib or ribociclib plus fulvestrant hormone receptor-positive human epidermal factor 2-negative metastatic breast cancer (HR+/HER2-MBC). We conducted a multicenter, retrospective cohort included 522 patients with HR+/HER2-MBC treated combination fulvestrant....
As a result of technological developments in healthcare services, telemedicine is becoming widespread. We aimed to determine the effect COVID-19 on Turkish medical oncologists' opinions through survey.This study was conducted using an online questionnaire linked invitation e-mail sent members Medical Oncology Association mailing group between May and July 2020.Of 110 (73 males 37 females) oncologists who answered questionnaire, average age 43.9 ± 7.29 (range: 31-64) years, majority...
No studies have evaluated the interaction, quality, and reliability of chemotherapy-related videos published on YouTube. The aim was to evaluate content YouTube about chemotherapy using 5 different scoring tools. In this cross-sectional register-based study, popular following keywords were examined; "chemotherapy," "what is chemotherapy," "types "chemotherapy side effects" treatments." Quality video measured modified DISCERN (mDISCERN), Journal American Medical Association (JAMA), Global...
Most of the studies on salivary gland cancers are limited for various reasons such as being single-center, small number patients, including only major or minor SGCs, epidemiological data.A total 37 medical oncology clinics from different regions Turkey participated in this retrospective-multicenter study. The analyzed data included clinical and demographical features, primary treatment, metastasis localizations, treatments includes certain pathologic features.The study a 443 SGCs. 56.7% was...
Myositis, an inflammatory disease affecting muscles, is a rare and potentially fatal immune-related adverse event associated with immune checkpoint inhibitors. There are limited data on its clinical features management.
for additional doses of vaccine to people in the risk group.On control breast USG performed on 27.08.2021;no recurrent mass and pathological LAP were observed.A second dose Biontech was 3 months later did not develop.Routine follow-up continues.
Background Triple negative breast cancer (TNBC) is characterized by high rates of recurrence, especially in patients with residual disease after neoadjuvant chemotherapy (NAC). Capecitabine being used as standard adjuvant treatment TNBC. We aimed to investigate the real-life data regarding efficacy capecitabine
We aimed to evaluate the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated pertuzumab plus taxane. reviewed medical records who were diagnosed Human Epidermal Growth Factor Receptor 2 (HER-2) positive received then TDM-1 between January 2014 2021 from twenty- five centers. The Kaplan- Meier method estimated progression-free survival (PFS) overall (OS). Additionally, objective response rate (ORR), clinical benefit (CBR), evaluated. One...
Abstract Background Neoadjuvant treatment is the standard in locally advanced ESCC. However, optimal chemotherapy regimen not known. Method This a retrospective observational cohort study conducted with propensity score matching. Patients resectable ESCC from 13 tertiary centers Türkiye were screened between January 2011 and December 2021. We compared efficacy safety of neoadjuvant chemoradiotherapy CF CROSS regimens patients Results Three hundred sixty‐two screened. who received induction (...
We aimed to compare FOLFIRI and bevacizumab with aflibercept in terms of overall survival (OS), progression-free (PFS) safety patients RAS-mutant metastatic colon cancer who progressed after first-line FOLFOX or XELOX treatment. This retrospective study included 243 from 15 different centres Turkey. The endpoints the were OS, PFS side effect outcomes. median age was 60 (21–85) years. Of enrolled study, 114 (46.9%) received 129 (53.1%) bevacizumab. Median OS 11.2 (95% CI: 9.1–13.2) months...
There is limited data on the effect of CDK 4/6 inhibitors in patients with advanced HR-positive and HER2-low tumors. Here we report real-life retrospectively collected from 448 ER-positive/HER2-negative breast cancer treated ribociclib palbociclib (only both them reimbursed) plus endocrine therapy June 2016 to 2022. The outcome HER2-0 (IHC score) (HER2 IHC score1+ 2+) tumors were compared. 443 female (98.9%). Median age was 58 (25-90). While HER2 score 0 295 (65.8%), 1-2 (HER2-low) 153...